- Home
- DXR vs MAIA Comparison
DXR vs MAIA Comparison
Compare DXR & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- MAIA
- Stock Information
- Founded
- DXR 1970
- MAIA 2018
- Country
- DXR United States
- MAIA United States
- Employees
- DXR N/A
- MAIA N/A
- Industry
- DXR Medical/Dental Instruments
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- MAIA Health Care
- Exchange
- DXR Nasdaq
- MAIA Nasdaq
- Market Cap
- DXR 40.3M
- MAIA 46.7M
- IPO Year
- DXR N/A
- MAIA 2022
- Fundamental
- Price
- DXR $7.77
- MAIA $1.99
- Analyst Decision
- DXR Strong Buy
- MAIA
- Analyst Count
- DXR 1
- MAIA 0
- Target Price
- DXR $25.00
- MAIA N/A
- AVG Volume (30 Days)
- DXR 5.2K
- MAIA 141.8K
- Earning Date
- DXR 01-01-0001
- MAIA 05-13-2025
- Dividend Yield
- DXR N/A
- MAIA N/A
- EPS Growth
- DXR 86.16
- MAIA N/A
- EPS
- DXR 0.11
- MAIA N/A
- Revenue
- DXR $119,714.00
- MAIA N/A
- Revenue This Year
- DXR N/A
- MAIA N/A
- Revenue Next Year
- DXR N/A
- MAIA N/A
- P/E Ratio
- DXR $71.76
- MAIA N/A
- Revenue Growth
- DXR N/A
- MAIA N/A
- 52 Week Low
- DXR $6.55
- MAIA $1.40
- 52 Week High
- DXR $10.00
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- DXR 49.33
- MAIA 63.83
- Support Level
- DXR $7.35
- MAIA $1.51
- Resistance Level
- DXR $7.98
- MAIA $2.25
- Average True Range (ATR)
- DXR 0.43
- MAIA 0.15
- MACD
- DXR -0.00
- MAIA 0.06
- Stochastic Oscillator
- DXR 52.94
- MAIA 62.94
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.